These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 18591266)

  • 1. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin.
    Lodise TP; Graves J; Evans A; Graffunder E; Helmecke M; Lomaestro BM; Stellrecht K
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3315-20. PubMed ID: 18591266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.
    Claeys KC; Zasowski EJ; Casapao AM; Lagnf AM; Nagel JL; Nguyen CT; Hallesy JA; Compton MT; Kaye KS; Levine DP; Davis SL; Rybak MJ
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5841-8. PubMed ID: 27431221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus.
    Casapao AM; Davis SL; McRoberts JP; Lagnf AM; Patel S; Kullar R; Levine DP; Rybak MJ
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4636-41. PubMed ID: 24890596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A stewardship program's retrospective evaluation of vancomycin AUC24/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.
    Gawronski KM; Goff DA; Brown J; Khadem TM; Bauer KA
    Clin Ther; 2013 Jun; 35(6):772-9. PubMed ID: 23795575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Moise PA; Smyth DS; El-Fawal N; Robinson DA; Holden PN; Forrest A; Sakoulas G
    J Antimicrob Chemother; 2008 Jan; 61(1):85-90. PubMed ID: 18042628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC >1 mg/L: A Multicenter Evaluation.
    Moise PA; Culshaw DL; Wong-Beringer A; Bensman J; Lamp KC; Smith WJ; Bauer K; Goff DA; Adamson R; Leuthner K; Virata MD; McKinnell JA; Chaudhry SB; Eskandarian R; Lodise T; Reyes K; Zervos MJ
    Clin Ther; 2016 Jan; 38(1):16-30. PubMed ID: 26585355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study.
    Moore CL; Osaki-Kiyan P; Haque NZ; Perri MB; Donabedian S; Zervos MJ
    Clin Infect Dis; 2012 Jan; 54(1):51-8. PubMed ID: 22109947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prior vancomycin use is a risk factor for reduced vancomycin susceptibility in methicillin-susceptible but not methicillin-resistant Staphylococcus aureus bacteremia.
    Mascitti KB; Edelstein PH; Fishman NO; Morales KH; Baltus AJ; Lautenbach E
    Infect Control Hosp Epidemiol; 2012 Feb; 33(2):160-6. PubMed ID: 22227985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methicillin-resistant Staphylococcus aureus (MRSA) staphylococcal cassette chromosome mec genotype effects outcomes of patients with healthcare-associated MRSA bacteremia independently of vancomycin minimum inhibitory concentration.
    Chen SY; Liao CH; Wang JL; Chiang WC; Lai MS; Chie WC; Chen WJ; Chang SC; Hsueh PR
    Clin Infect Dis; 2012 Nov; 55(10):1329-37. PubMed ID: 22911641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?
    Lodise TP; Drusano GL; Zasowski E; Dihmess A; Lazariu V; Cosler L; McNutt LA
    Clin Infect Dis; 2014 Sep; 59(5):666-75. PubMed ID: 24867791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determining vancomycin Etest MICs in patients with MRSA bloodstream infection does not support switching antimicrobials.
    Hos NJ; Jazmati N; Stefanik D; Hellmich M; AlSael H; Kern WV; Rieg S; Wisplinghoff H; Seifert H; Kaasch AJ
    J Infect; 2017 Mar; 74(3):248-259. PubMed ID: 28017826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantifying the matrix of relationships between reduced vancomycin susceptibility phenotypes and outcomes among patients with MRSA bloodstream infections treated with vancomycin .
    Lodise TP; Drusano GL; Lazariu V; El-Fawal N; Evans A; Graffunder E; Stellrecht K; Mendes RE; Jones RN; Cosler L; McNutt LA
    J Antimicrob Chemother; 2014 Sep; 69(9):2547-55. PubMed ID: 24840624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.
    Soriano A; Marco F; Martínez JA; Pisos E; Almela M; Dimova VP; Alamo D; Ortega M; Lopez J; Mensa J
    Clin Infect Dis; 2008 Jan; 46(2):193-200. PubMed ID: 18171250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early response assessment to guide management of methicillin-resistant Staphylococcus aureus bloodstream infections with vancomycin therapy.
    Joo J; Yamaki J; Lou M; Hshieh S; Chu T; Shriner KA; Wong-Beringer A
    Clin Ther; 2013 Jul; 35(7):995-1004. PubMed ID: 23829982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
    Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
    Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting high vancomycin minimum inhibitory concentration isolate infection among patients with community-onset methicillin-resistant Staphylococcus aureus bacteraemia.
    Chen SY; Hsueh PR; Chiang WC; Huang EP; Lin CF; Chang CH; Chen SC; Chen WJ; Chang SC; Lai MS; Chie WC
    J Infect; 2014 Sep; 69(3):259-65. PubMed ID: 24797078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of failure in vancomycin-treated methicillin-resistant Staphylococcus aureus bloodstream infection: a clinically useful risk stratification tool.
    Moore CL; Lu M; Cheema F; Osaki-Kiyan P; Perri MB; Donabedian S; Haque NZ; Zervos MJ
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4581-8. PubMed ID: 21825294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence of isolates with reduced glycopeptide susceptibility in persistent or recurrent bloodstream infections due to methicillin-resistant Staphylococcus aureus.
    Uçkay I; Bernard L; Buzzi M; Harbarth S; François P; Huggler E; Ferry T; Schrenzel J; Renzoni A; Vaudaux P; Lew DP
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1258-64. PubMed ID: 22155824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of vancomycin MIC creep on patients with methicillin-resistant Staphylococcus aureus bacteremia.
    Yeh YC; Yeh KM; Lin TY; Chiu SK; Yang YS; Wang YC; Lin JC
    J Microbiol Immunol Infect; 2012 Jun; 45(3):214-20. PubMed ID: 22571999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More accurate measurement of vancomycin minimum inhibitory concentration indicates poor outcomes in meticillin-resistant Staphylococcus aureus bacteraemia.
    Shoji H; Maeda M; Shirakura T; Takuma T; Ugajin K; Fukuchi K; Ishino K; Niki Y
    Int J Antimicrob Agents; 2015 Nov; 46(5):532-7. PubMed ID: 26364848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.